Evidence map›Paper›PMID 39749695›Full record

ArticleCancer communications (London, England)2025

Efficient 5-ALA-photodynamic therapy in nasopharyngeal carcinoma induces an immunoactivation mediated by tumoral extracellular vesicles and associated with immunogenic cell death.

Camille Trioën, Thomas Soulier, Jacquie Massoud, Clément Bouchez, Nicolas Stoup, Anthony Lefebvre, Anne-Sophie Dewalle, Guillaume Paul Grolez, Nadira Delhem, Olivier Moralès

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Camille TrioënOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Thomas SoulierOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Jacquie MassoudOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Clément BouchezOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Nicolas StoupOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Anthony LefebvreOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Anne-Sophie DewalleOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Guillaume Paul GrolezOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Nadira DelhemOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.
Olivier MoralèsOncoThaï INSERM U1189, CHU Lille, University of Lille, Lille, Haut de France, France.ORCID https://orcid.org/0000-0002-2135-3265

Funding

Région des Hauts-de-Franceuniversity of Lille
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39749695
PMCPMC11999885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.